Case-fatality rate of SARS-CoV-2 infection during the third and fifth epidemic waves in SpainImpact of vaccination (Pag.-e 102026)

  1. V. Martín-Sánchez 1
  2. A. Ruiz-Garcia 2
  3. F. Vitelli-Storelli 1
  4. A. Serrano-Cumplido 3
  5. A. Barquilla-Garcia 4
  6. R.M. Micó-Pérez 5
  7. V. Olmo-Quintana 6
  8. A. Calderón-Montero 7
  9. A. Segura-Fragoso 8
  1. 1 University of León, León, Spain
  2. 2 Madrid Health Service (SERMAS), Department of Health, Spain
  3. 3 Getxo, Bizkaia, Spain
  4. 4 EAP de Trujillo, Extremadura Health Service, Cáceres, Spain
  5. 5 Fontanars dels Alforins Health Center, Xàtiva-Ontinyent
  6. 6 Hospital Dr. Negrín Gran Canaria Las Palmas (CEI/CEIm)
  7. 7 Doctor Pedro Laín Entralgo Health Center, Madrid Health Service
  8. 8 Health Science Department, Castilla La Mancha University, Talavera de la Reina, Toledo, Spain
Show affiliations +
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2023

Issue: 7

Pages: 5-5

Type: Article

DOI: 10.1016/J.SEMERG.2023.102026 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Abstract

Introduction During the first and second epidemic waves in Spain, the SARS-CoV-2 case-fatality rates (CFRs) showed significant differences between Autonomous Communities (ACs). Comparing CFRs in the third and fifth epidemic waves can provide information on the impact of the different vaccination coverages in the ACs. Objective To evaluate the impact of vaccination on COVID-19 CFRs in the third and fifth epidemic waves in Spain, according to sex, age, and AC. Methods This work is an observational, descriptive study which uses data on COVID-19 infections, deaths, and vaccinees published by the Spanish Ministry of Health and the regional Health Departments of the ACs. The third epidemic wave was defined as the period from 26th December 2020 to 19th April 2021, and the fifth wave, from 19th July to 19th September 2021. The CFRs (deaths per 1000 infected [‰]) were calculated according to sex, age group, and AC. The standardized case-fatality ratio (SCFR) was adjusted for age and sex for each wave. We estimated the correlation between CFRs and their change between the two epidemic waves with the vaccination coverages reached at the beginning of the fifth wave. Results The CFR in the fifth wave (5.7‰) was lower than in the third wave (16.5‰). In addition, the CFR in both waves was significantly higher in men than in women, and in older people than in younger ones. A decrease in the CFR between both waves was only observed in those older than 49. A strong direct and positive correlation (R2a = 0.8399) was found between vaccination coverage by age group and decrease in CFR between both epidemic waves. Significant differences were seen between ACs in the two waves, as regards both CFRs and SCFRs. When comparing ACs, a direct correlation was observed between vaccination coverage and CFRs in the fifth wave, and also – although weak – between vaccination coverage and decrease in CFR between both waves. Conclusion The CFR significantly decreased in Spain between the third and the fifth epidemic waves in population aged 50 or older, probably due to the high vaccination coverage in that age group. Differences were observed between CFRs and SCFRs between ACs that are not explained by the differences in vaccination coverage, suggesting the need for further research and evaluation.

Bibliographic References

  • V. Martín-Sánchez, A. Barquilla-García, F. Vitelli-Stotelli, A. Segura-Fragoso, A. Ruiz-García, A. Serrano-Cumplido, et al. Análisis de las tasas de letalidad de la infección por SARS-CoV-2 en las Comunidades Autónomas de España Semergen, 46 (Suppl. 1) (2020), pp. 12-19, 10.1016/j.semerg.2020.06.013 View PDFView articleView in ScopusGoogle Scholar
  • M. Pollán, B. Pérez-Gómez, R. Pastor-Barriuso, J. Oteo, M.A. Hernán, M. Pérez-Olmeda, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Lancet, 396 (2020), pp. 535-544, 10.1016/S0140-6736(20)31483-5 View PDFView articleGoogle Scholar
  • V. Martín-Sánchez, A. Calderón-Montero, A. Barquilla-García, F. Vitelli-Storelli, A. Segura-Fragoso, V. Olmo-Quintana, et al. Analysis of case fatality rate of SARS-CoV-2 infection in the Spanish Autonomous Communities between March and May 2020 PLoS One, 16 (2021), p. e0260769, 10.1371/journal.pone.0260769 View article View in ScopusGoogle Scholar
  • A. Ruiz-García, F. Vitelli-Storelli, A. Serrano-Cumplido, A. Segura-Fragoso, A. Calderón-Montero, V. Martín-Sánchez, et al. Tasas de letalidad por SARS-CoV-2 durante la segunda onda epidémica en España según Comunidades Autónomas Semergen, 48 (2022), pp. 252-262, 10.1016/j.semerg.2022.02.004 View PDFView articleView in ScopusGoogle Scholar
  • C.J. Clopper, E.S. Pearson The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika, 26 (1934), pp. 404-413 Google Scholar
  • M.S. Dhar, R. Marwal, V.S. Radhakrishnan, K. Ponnusamy, B. Jolly, R.C. Bhoyar, et al. Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India Science, 374 (2021), pp. 995-999, 10.1101/2021.06.02.21258076 View PDF This article is free to access. View in ScopusGoogle Scholar
  • D.W. Eyre, D. Taylor, M. Purver, D. Chapman, T. Fowler, K.B. Pouwels, et al. Effect of Covid-19 vaccination on transmission of Alpha and Delta variants N Engl J Med, 386 (2022), pp. 744-756, 10.1056/NEJMoa2116597 View articleView in ScopusGoogle Scholar
  • J.P.A. Ioannidis Infection fatality rate of COVID-19 inferred from seroprevalence data Bull World Health Organ, 99 (2021), 10.2471/BLT.20.265892 19–33F View article Google Scholar
  • John Hopkins University Coronavirus Resource Centre. COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU). Available from: https://coronavirus.jhu.edu/map.html [accessed 03.05.22]. Google Scholar
  • G. Luo, X. Zhang, H. Zheng, D. He Infection fatality ratio and case fatality ratio of COVID-19 Int J Infect Dis, 113 (2021), pp. 43-46, 10.1016/j.ijid.2021.10.004 View PDFView articleView in ScopusGoogle Scholar
  • E. Mahase Omicron: South Africa says fourth wave peak has passed as it lifts curfew BMJ, 376 (2022), p. o7, 10.1136/bmj.o7 View article View in ScopusGoogle Scholar
  • S. Lorenzo-Herrero, C. Sordo-Bahamonde, S. González Respuesta inmune e inflamatoria en el envejecimiento Sociedad Española de Geriatría y Gerontología (2021) Available from: https://www.segg.es/actualidad-segg/2021/06/10/respuesta-inmune-e-inflamatoria-en-el-envejecimiento [accessed 03.05.22] Google Scholar
  • S. Cinza-Sanjurjo, R.M. Micó-Pérez, S. Velilla-Zancada, M.A. Prieto-Díaz, G.C. Rodríguez-Roca, A. Barquilla García, et al. Factores asociados al riesgo cardiovascular y enfermedad cardiovascular y renal en el estudio IBERICAN (Identificación de la poBlación Española de RIesgo CArdiovascular y reNal): resultados definitivos Semergen, 46 (2020), pp. 368-378, 10.1016/j.semerg.2020.06.027 View PDFView articleView in ScopusGoogle Scholar
  • V. Hall, S. Foulkes, F. Insalata, P. Kirwan, A. Saei, A. Atti, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection N Engl J Med, 13 (2022), pp. 1207-1220, 10.1056/NEJMoa2118691 View articleView in ScopusGoogle Scholar
  • Y. Goldberg, M. Mandel, Y.M. Bar-On, O. Bodenheimer, L. Freedman, E.J. Haas, et al. Waning immunity after the BNT162b2 vaccine in Israel N Engl J Med, 385 (2021), p. e85, 10.1056/NEJMoa2114228 View articleView in ScopusGoogle Scholar
  • E.G. Levin, Y. Lustig, C. Cohen, R. Fluss, V. Indenbaum, S. Amit, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months N Engl J Med, 385 (2021), p. e84, 10.1056/NEJMoa2114583 View articleView in ScopusGoogle Scholar
  • Y. Alimohamadi, H.H. Tola, A. Abbasi-Ghahramanloo, M. Janani, M. Sepandi Case fatality rate of COVID-19: a systematic review and meta-analysis J Prev Med Hyg, 62 (2021), pp. E311-E320, 10.15167/2421-4248/jpmh2021.62.2.1627 View article View in ScopusGoogle Scholar
  • G. Sorci, B. Faivre, S. Morand Explaining among-country variation in COVID-19 case fatality rate Sci Rep, 10 (2020), p. 18909, 10.1038/s41598-020-75848-2 View PDF This article is free to access. View in ScopusGoogle Scholar
  • K.A. Twohig, T. Nyberg, A. Zaidi, S. Thelwall, M.A. Sinnathamby, S. Aliabadi, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study Lancet Infect Dis, 22 (2022), pp. 35-42, 10.1016/S1473-3099(21)00475-8 View PDFView articleView in ScopusGoogle Scholar
  • A. Sheikh, C. Robertson, B. Taylor BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the Delta variant N Engl J Med, 385 (2021), p. 23, 10.1056/NEJMc2113864 View articleGoogle Scholar
  • M. Voysey, S.A.C. Clemens, S.A. Madhi, L.Y. Weckx, P.M. Folegatti, P.K. Aley, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Lancet, 397 (2021), pp. 99-111, 10.1016/S0140-6736(20)32661-1 View PDFView articleView in ScopusGoogle Scholar
  • P. Tang, M.R. Hasan, H. Chemaitelly, H.M. Yassine, F.M. Benslimane, H.A. Al Khatib, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar Nat Med, 27 (2021), pp. 2136-2143, 10.1038/s41591-021-01583-4 View PDF This article is free to access. View in ScopusGoogle Scholar
  • C.H. Bozio, S.J. Grannis, A.L. Naleway, T.C. Ong, K.A. Butterfield, M.B. DeSilva, et al. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity – nine states, January–September 2021 MMWR Morb Mortal Wkly Rep, 70 (2021), pp. 1539-1544 Available from: https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7044e1-H.pdf [accessed 03.05.22] View article CrossRefView in ScopusGoogle Scholar
  • A. Britton, K.E. Fleming-Dutra, N. Shang, Z.R. Smith, T. Dorji, G. Derado, et al. Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and Delta variant predominance JAMA, 327 (2022), pp. 1032-1041, 10.1001/jama.2022.2068 View PDF This article is free to access. View in ScopusGoogle Scholar
  • V.P. Papadopoulos, A. Emmanouilidou, M. Yerou, S. Panagaris, C. Souleiman, D. Varela, et al. SARS-CoV-2 vaccination coverage and key public health indicators may explain disparities in COVID-19 country-specific case fatality rate within European economic area Cureus, 14 (2022), p. e22989, 10.7759/cureus.22989 [Epub 14.04.22; PubMed PMID: 35415037; PubMed Central PMCID: PMCPMC8994019] View article Google Scholar
  • C. Mattiuzzi, B.M. Henry, G. Lippi COVID-19 vaccination uptake strongly predicts averted deaths of older people across Europe Biomed J (2022), 10.1016/j.bj.2022.01.014 [Epub 31.01.22; PubMed PMID: 35093609; PubMed Central PMCID: PMCPMC8795713] View PDF This article is free to access. Google Scholar
  • Q. Ma, J. Liu, Q. Liu, L. Kang, R. Liu, W. Jing, et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis JAMA Netw Open, 4 (2021), p. e2137257, 10.1001/jamanetworkopen.2021.37257 View PDF This article is free to access. View in ScopusGoogle Scholar
Data source: Dialnet